These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 33142025)

  • 21. Genetic testing and familial implications in breast-ovarian cancer families.
    Oosterwijk JC; de Vries J; Mourits MJ; de Bock GH
    Maturitas; 2014 Aug; 78(4):252-7. PubMed ID: 24894332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Lack of referral for genetic counseling and testing in BRCA1/2 and Lynch syndromes: a nationwide study based on 240,134 consultations and 134,652 genetic tests.
    Pujol P; Lyonnet DS; Frebourg T; Blin J; Picot MC; Lasset C; Dugast C; Berthet P; de Paillerets BB; Sobol H; Grandjouan S; Soubrier F; Buecher B; Guimbaud R; Lidereau R; Jonveaux P; Houdayer C; Giraud S; Olschwang S; Nogue E; Galibert V; Bara C; Nowak F; Khayat D; Nogues C
    Breast Cancer Res Treat; 2013 Aug; 141(1):135-44. PubMed ID: 23974829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Talking across generations: Family communication about BRCA1 and BRCA2 genetic cancer risk.
    Young AL; Butow PN; Rhodes P; Tucker KM; Williams R; Healey E; Wakefield CE
    J Genet Couns; 2019 Jun; 28(3):516-532. PubMed ID: 30694012
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Investigating barriers to genetic counseling and germline mutation testing in women with suspected hereditary breast and ovarian cancer syndrome and Lynch syndrome.
    Shaw J; Bulsara C; Cohen PA; Gryta M; Nichols CB; Schofield L; O'Sullivan S; Pachter N; Hardcastle SJ
    Patient Educ Couns; 2018 May; 101(5):938-944. PubMed ID: 29273311
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Family health beliefs and cascade genetic testing in Asian families with hereditary cancer risk: "Okay, now what?".
    Tran L; Young JL; Barton CM; Hodan R; Hanson-Kahn A; Chun N
    J Genet Couns; 2024 Mar; ():. PubMed ID: 38504135
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risk assessment and genetic counseling for hereditary breast and ovarian cancer syndromes-Practice resource of the National Society of Genetic Counselors.
    Berliner JL; Cummings SA; Boldt Burnett B; Ricker CN
    J Genet Couns; 2021 Apr; 30(2):342-360. PubMed ID: 33410258
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
    Arai M; Iwase T; Takazawa Y; Takeshima N
    Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Communicating genetic test results within the family: Is it lost in translation? A survey of relatives in the randomized six-step study.
    Daly MB; Montgomery S; Bingler R; Ruth K
    Fam Cancer; 2016 Oct; 15(4):697-706. PubMed ID: 26897130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Testing for hereditary breast and ovarian cancer in the southeastern United States.
    Miron A; Schildkraut JM; Rimer BK; Winer EP; Sugg Skinner C; Futreal PA; Culler D; Calingaert B; Clark S; Kelly Marcom P; Iglehart JD
    Ann Surg; 2000 May; 231(5):624-34. PubMed ID: 10767783
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic uptake in BRCA-mutation families is related to emotional and behavioral communication characteristics of index patients.
    Landsbergen K; Verhaak C; Kraaimaat F; Hoogerbrugge N
    Fam Cancer; 2005; 4(2):115-9. PubMed ID: 15951961
    [TBL] [Abstract][Full Text] [Related]  

  • 33. "Second-Class Status?" Insight into Communication Patterns and Common Concerns Among Men with Hereditary Breast and Ovarian Cancer Syndrome.
    Suttman A; Pilarski R; Agnese DM; Senter L
    J Genet Couns; 2018 Aug; 27(4):885-893. PubMed ID: 29404823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Uptake of Cascade Genetic Testing for Hereditary Breast and Ovarian Cancer: A Systematic Review and Meta-Analysis.
    Ahsan MD; Chandler IR; Min S; Grant B; Primiano M; Greenwald J; Soussana TN; Baltich Nelson B; Thomas C; Chapman-Davis E; Sharaf RN; Frey MK
    Clin Obstet Gynecol; 2024 Dec; 67(4):702-710. PubMed ID: 39431491
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multi-gene panel testing for hereditary cancer predisposition in unsolved high-risk breast and ovarian cancer patients.
    Crawford B; Adams SB; Sittler T; van den Akker J; Chan S; Leitner O; Ryan L; Gil E; van 't Veer L
    Breast Cancer Res Treat; 2017 Jun; 163(2):383-390. PubMed ID: 28281021
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Factors Associated with Interest in Gene-Panel Testing and Risk Communication Preferences in Women from BRCA1/2 Negative Families.
    Flores KG; Steffen LE; McLouth CJ; Vicuña BE; Gammon A; Kohlmann W; Vigil L; Dayao ZR; Royce ME; Kinney AY
    J Genet Couns; 2017 Jun; 26(3):480-490. PubMed ID: 27496122
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel candidates of pathogenic variants of the BRCA1 and BRCA2 genes from a dataset of 3,552 Japanese whole genomes (3.5KJPNv2).
    Tokunaga H; Iida K; Hozawa A; Ogishima S; Watanabe Y; Shigeta S; Shimada M; Yamaguchi-Kabata Y; Tadaka S; Katsuoka F; Ito S; Kumada K; Hamanaka Y; Fuse N; Kinoshita K; Yamamoto M; Yaegashi N; Yasuda J
    PLoS One; 2021; 16(1):e0236907. PubMed ID: 33428613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Screening for common mutations in BRCA1 and BRCA2 genes: interest in genetic testing of Tunisian families with breast and/or ovarian cancer.
    Fourati A; Louchez MM; Fournier J; Gamoudi A; Rahal K; El May MV; El May A; Revillion F; Peyrat JP
    Bull Cancer; 2014 Nov; 101(11):E36-40. PubMed ID: 25418591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Predictive testing for hereditary breast and ovarian cancer: a psychological framework for pre-test counselling.
    Decruyenaere M; Evers-Kiebooms G; Denayer L; Welkenhuysen M; Claes E; Legius E; Demyttenaere K
    Eur J Hum Genet; 2000 Feb; 8(2):130-6. PubMed ID: 10757645
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.